Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Total Non-Current Liabilities (2020 - 2021)

Rani Therapeutics Holdings has reported Total Non-Current Liabilities over the past 2 years, most recently at $2.6 million for Q4 2021.

  • Quarterly results put Total Non-Current Liabilities at $2.6 million for Q4 2021, down 65.8% from a year ago — trailing twelve months through Dec 2021 was $2.6 million (down 65.8% YoY), and the annual figure for FY2021 was $2.6 million, down 65.8%.
  • Total Non-Current Liabilities for Q4 2021 was $2.6 million at Rani Therapeutics Holdings, down from $5.2 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for RANI hit a ceiling of $10.0 million in Q2 2021 and a floor of $2.6 million in Q4 2021.